Early development of pembrolizumab‐induced fulminant myositis and cardiotoxicity in a patient with metastatic thymoma-Reference-Cited by-同舟云学术

Early development of pembrolizumab‐induced fulminant myositis and cardiotoxicity in a patient with metastatic thymoma

Published:2022-08-24 Issue:9 Volume:10 Page:
ISSN:2051-3380
Container-title:Respirology Case Reports
language:en
Short-container-title:Respirology Case Reports

Author:

Jang Soo Yeon¹^ORCID,Lee Sung Yong¹^ORCID,Lee Hye Lim²^ORCID,Choi Juwhan¹^ORCID

Affiliation:

1. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine Korea University Guro Hospital, Korea University College of Medicine Seoul Republic of Korea

2. Department of Neurology Korea University Guro Hospital, Korea University College of Medicine Seoul Republic of Korea

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/rcr2.1025

Reference7 articles.

1. Neurologic complications of immune checkpoint inhibitors

2. Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report

3. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors

4. PD-1 checkpoint inhibition: Toxicities and management

5. Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiotoxicity of immunotherapy in lung cancer in light of new ESC guidelines;Annales Academiae Medicae Silesiensis;2023-08-18

2. Immunomodulatory drug-induced hypophysitis and other immunomodulatory adverse reactions in multiple organ systems;Side Effects of Drugs Annual;2023

3. Multiple drugs;Reactions Weekly;2022-10-01